Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
28 authors.
Qing Wang *Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.ORCID 0000-0002-5520-4495
Francesco Boccalatte *Department of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0003-1732-2033
Jason Xu *Graduate Group in Genomics and Computational Biology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.ORCID 0000-0002-9061-3593
Giovanni GambiDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-2318-0003
Bettina NadorpDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0003-1974-8425
Fatema AkterDivision of Hematology-Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.ORCID 0009-0004-6080-8164
Carea MullinDivision of Hematology-Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.ORCID 0009-0009-4487-2779
Ashley F MelnickCellular and Molecular Biology Program, University of Michigan School of Medicine , Ann Arbor, MI, USA.ORCID 0000-0001-5880-3074
Elizabeth ChoeDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0005-0808-0740
Anna C McCarterDepartment of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0003-3828-9797
Nicole A JeromeCancer Biology Program, University of Michigan School of Medicine , Ann Arbor, MI, USA.ORCID 0009-0001-9251-0408
Siyi ChenDivision of Hematology-Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.ORCID 0000-0002-0153-6152
Karena LinCellular and Molecular Biology Program, University of Michigan School of Medicine , Ann Arbor, MI, USA.ORCID 0000-0002-8429-6325
Sarah KhanDivision of Hematology-Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.ORCID 0000-0001-6018-7290
Rohan KodguleDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-1711-8641
Jonathan H SussmanGraduate Group in Genomics and Computational Biology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.ORCID 0000-0002-3057-3550
Petri PölönenDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0001-6128-9985
Javier Rodriguez-HernaezDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0001-5549-0463
Sonali NarangDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-1138-0067
Kleopatra AvrampouDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0009-0008-4422-5064
Bryan KingDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0003-1203-784X
Aristotelis TsirigosDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-7512-8477
Russell J H RyanDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-8174-3962
Charles G MullighanDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-1871-1850
David T TeacheyDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0001-7373-8987
Kai TanDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0002-9104-5567
Iannis AifantisDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0001-6857-1035
Mark Y ChiangDivision of Hematology-Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.ORCID 0000-0003-2099-0956
Funding
MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
The impact of changes in chromatin architecture on cancer phenotypes and tumor progressionP01CA229086 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Giorgio Inghirami · 2019 to 2026
$17.0M
Role of TET2 mutations in malignant transformation and acute myeloid leukemiaR01CA173636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2013 to 2022
$6.3M
Cellular and Molecular Biology at MichiganT32GM145470 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI John Chadwick Brenner · 2022 to 2026
$4.1M
Targeting Epigenetic Heterogeneity in Pediatric T cell leukemia: Epi-Clones as Drivers of ChemoresistanceR01CA252239 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aristotelis Tsirigos · 2021 to 2026
$3.7M
Targeting an RNA Binding Protein Network in Acute Myeloid LeukemiaR01CA242020 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, AIFANTIS, IANNIS · 2020 to 2024
$2.7M
mRNA stability and its impact on hematopoiesis and acute leukemiaR01CA266212 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Iannis Aifantis · 2022 to 2026
$2.7M
Mechanisms of enhancer regulation in leukemiaR01CA228135 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2019 to 2023
$2.5M
Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell developmentR01AI136941 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHIANG, MARK Y · 2019 to 2023
$2.5M
Mapping and targeting 3D regulatory elements in leukemia and lymphoma-SupplementR01CA298153 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Iannis Aifantis, Aristotelis Tsirigos · 2025 to 2026
$1.9M
Direct coregulation of Notch1 by Zmiz1 in T-cell leukemiaR01CA196604 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHIANG, MARK Y · 2015 to 2019
$1.8M
Analysis of Developmental Arrest and Treatment Resistance in High-risk T-ALLF30CA268782 · NCI · UNIVERSITY OF PENNSYLVANIA · PI XU, JASON · 2022 to 2024
$141k
Alex's Lemonade StandAlex's Lemonade Stand Foundation for childhood cancerAmerican-Italian Cancer FoundationAssociazione Italiana per la Ricerca sul Cancro 26533Michigan Medicine Rogel Cancer CenterNational Institute of Allergy and Infectious Diseases R01AI136941NCI NIH HHS F30 CA268782NCI NIH HHS F31 CA260929NCI NIH HHS P01 CA229086NCI NIH HHS R01 CA173636NCI NIH HHS R01 CA196604NCI NIH HHS R01CA196604NCI NIH HHS R01 CA228135NCI NIH HHS R01 CA242020NCI NIH HHS R01 CA252239NCI NIH HHS R01 CA266212NCI NIH HHS R01 CA298153NIAID NIH HHS R01 AI136941NIGMS NIH HHS T32 GM007863NIGMS NIH HHS T32 GM145470NIH HHS T32GM145470Rally Foundation for Childhood Cancer ResearchSt. Baldricks FoundationVogelstein Family Foundation
6 · The paper itself
Abstract
While the mutational landscape across early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) and ETP-like leukemia is known, establishing a unified framework that activates stem cell genes characteristic of these tumors remains elusive. Using complementary mouse and human models, chromatin mapping, and enhancer profiling, we show that the coactivator ZMIZ1 promotes normal and malignant ETP population growth by inducing the transcription factor MYB in feedforward circuits to convergently activate oncogenes (MEF2C, MYCN, and BCL2) through essential enhancers. A key superenhancer, the N-Myc regulating enhancer (NMRE), drives malignant ETP population growth but is dispensable for normal lymphopoiesis. This network of stem cell superenhancers identifies treatment-resistant tumors and poor survival outcomes; unifies diverse ETP-ALLs; and contributes to cardinal features of the recently genomically identified high-risk bone marrow progenitor-like (BMP-like) ETP-ALL tumor-stem cell/myeloid gene expression, inhibited NOTCH1-induced T-cell development, aggressive clinical behavior, and venetoclax sensitivity. Since ZMIZ1 is dispensable for essential homeostasis, it might be possible to safely target this network to treat high-risk diseases.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Native stem cell transcriptional circuits define cardinal features of high-risk leukemia. · full record | OpenQuestion